BURLINGTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-founder and Chief Executive Officer of the Company, will present at two upcoming investor conferences.
Details of the presentations can be found below.
Morgan Stanley Global Healthcare Conference
Format: Fireside Chat
Date: 09/06/2024
Time: 10:45 AM ET
H.C. Wainwright 26th Annual Global Investment Conference
Format: Company Presentation
Date: 09/09/2024
Time: 2:00 PM ET
Webcast replays will be accessible following the live sessions on the Events page of the Investors section on the Company’s website at https://ir.fractyl.com/.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or https://twitter.com/FractylHealth.
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it., 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it., 978.760.5622
Investor Contact
Stephen Jasper, Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it., 619.949.3681
| Last Trade: | US$1.99 |
| Daily Change: | 0.05 2.58 |
| Daily Volume: | 402,208 |
| Market Cap: | US$95.720M |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
